Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience.
Özkan AlanTuğba Akın TelliTugba Basoglu TuyluRukiye ArikanNazim Can DemircanOzlem ErcelepSerap KayaNalan Akgul BabacanBeste M AtasoySuheyla BozkurtYasar BayriDilek GulGazanfer EkinciIbrahim ZiyalFaysal DanePerran Fulden YumukPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.